Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024
July 31, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the...
Verisk Reports Second-Quarter 2024 Financial Results
July 31, 2024 07:15 ET
|
Verisk Analytics, Inc.
Consolidated revenues were $717 million, up 6.2%, and up 6.0% on an organic constant currency (OCC) basis for the second quarter of 2024.Income from continuing operations was $308 million,...
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
July 31, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
July 31, 2024 07:00 ET
|
Fulcrum Therapeutics, Inc.
― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024 ― ― Entered into a collaboration and ex-U.S....
Katapult to Announce Second Quarter 2024 Financial Results on August 14, 2024
July 31, 2024 07:00 ET
|
Katapult Holdings, Inc.
Katapult to release Q2 2024 financial results on Aug 14 2024
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024
July 31, 2024 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, July 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
Lantheus Reports Second Quarter 2024 Financial Results
July 31, 2024 07:00 ET
|
Lantheus Holdings, Inc.
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023Completed three strategic transactions to expand innovative pipelineGAAP fully diluted...
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
July 31, 2024 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
July 31, 2024 07:00 ET
|
Amarin Corporation plc
-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize...
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
July 31, 2024 07:00 ET
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...